|
|
News Breaks | | | | November 12, 2012 | | 16:37 EDT |  | WX | WuXi PharmaTech narrows FY12 revenue view to $495M-$498M from $488M-$498M
FY12 consensus $496.85M. Sees FY12 operating margin of about 17.5% on a GAAP basis and about 20.5% on a non-GAAP basis, compared to previous guidance of 17%-18.0% and 20.0%-21.0%, respectively. | |
|
News For WX From The Last 14 Days Check below for free stories on WX the last two weeks. |
|
|
| May 20, 2013 | | 07:34 EDT |  | WX | UBS to host a conference
 Subscribe for More Information | | | May 14, 2013 | | 07:55 EDT |  | WX | WuXi PharmaTech 2H13 guidance looks conservative, says Wells Fargo
After WuXi reported stronger than expected Q1 results, Wells Fargo notes that the company did not raise its full year 2013 guidance. The firm views the guidance as conservative, and it thinks the company's forecast of stable margins in 2013 versus 2012 is positive. However, the firm keeps a Sector Perform rating on the shares. | | | May 13, 2013 | | 16:40 EDT | | WX | WuXi PharmaTech sees FY13 EPS $1.49-$1.53, consensus $1.47
Subscribe for More Information | | | 16:39 EDT | | WX | WuXi PharmaTech sees Q2 EPS 39c-40c, consensus 36c
Subscribe for More Information | | | 16:38 EDT | | WX | WuXi PharmaTech reports Q1 EPS 35c, consensus 31c
Reports Q1 revenue $131.9M, consensus $130.02M. | |
|
|
|
|
|
|
